Want to see IN:PANACEABIO full AI Analyst Report?
PANACEABIO Stock Chart & Stats
₹440.65
-₹8.10(-1.84%)
At close: 4:00 PM EDT
₹440.65
-₹8.10(-1.84%)
Day’s Range― - ―
52-Week Range₹293.10 - ₹647.50
Previous CloseN/A
Volume125.06K
Average Volume (3M)12.46K
Market Cap
₹23.40B
Enterprise Value₹24.23K
Total Cash (Recent Filing)₹744.00M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding61,250,744
10 Day Avg. Volume6,832
30 Day Avg. Volume12,457
Financial Highlights & Ratios
PEG Ratio9.41
Price to Book (P/B)2.16
Price to Sales (P/S)2.82
P/FCF Ratio-49.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe sustained revenue recovery since FY2023 indicates improving demand for the company’s pharmaceutical and biotechnology offerings. Continued growth provides a foundation for operating leverage if management can convert higher sales into consistent profitability.
Low Leverage And Stable EquityVery low leverage and a sizable, stable equity base provide financial flexibility during periods of weak profitability. This conservative balance sheet can support investment in products and operations while reducing dependence on external financing.
Improved Operating Cash FlowThe return to positive operating cash flow is an encouraging step toward self-funded operations. If maintained, it could reduce pressure on the balance sheet and improve the company’s ability to fund pharmaceutical and vaccine activities internally.
Bears Say
Persistent Net LossesContinued losses show that revenue growth has not yet translated into an economically sustainable business. Persistent unprofitability can constrain reinvestment, weaken returns on equity, and make future performance dependent on operational improvements that are not yet established.
Negative Free Cash FlowRepeated negative free cash flow indicates ongoing cash absorption or elevated investment needs despite the conservative balance sheet. Unless cash conversion improves, the company may have less flexibility to expand, develop products, or withstand operating setbacks.
Volatile And Unsustainable MarginsThe lack of consistent margins makes future earnings quality difficult to assess and suggests that revenue growth alone may not deliver durable shareholder returns. A non-recurring profitable year followed by losses highlights unresolved operating or product-mix challenges.
Panacea Biotec Limited News
PANACEABIO FAQ
What was Panacea Biotec Limited’s price range in the past 12 months?
Panacea Biotec Limited lowest stock price was ₹293.10 and its highest was ₹647.50 in the past 12 months.
What is Panacea Biotec Limited’s market cap?
Panacea Biotec Limited’s market cap is ₹23.40B.
When is Panacea Biotec Limited’s upcoming earnings report date?
Panacea Biotec Limited’s upcoming earnings report date is Nov 18, 2026 which is in 75 days.
How were Panacea Biotec Limited’s earnings last quarter?
Panacea Biotec Limited released its earnings results on Aug 13, 2026. The company reported ₹0.376 earnings per share for the quarter.
Is Panacea Biotec Limited overvalued?
According to Wall Street analysts Panacea Biotec Limited’s price is currently Overvalued.
Does Panacea Biotec Limited pay dividends?
Panacea Biotec Limited pays a Annually dividend of ₹0.75 which represents an annual dividend yield of N/A. See more information on Panacea Biotec Limited dividends here
What is Panacea Biotec Limited’s EPS estimate?
Panacea Biotec Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Panacea Biotec Limited have?
Panacea Biotec Limited has 61,250,744 shares outstanding.
What happened to Panacea Biotec Limited’s price movement after its last earnings report?
Panacea Biotec Limited reported an EPS of ₹0.376 in its last earnings report. Following the earnings report the stock price went up 3.5%.
Which hedge fund is a major shareholder of Panacea Biotec Limited?
Currently, no hedge funds are holding shares in IN:PANACEABIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Panacea Biotec Limited
Established in 1984 and headquartered in New Delhi, India, Panacea Biotec Limited is a biotechnology company dedicated to the innovation, production, and commercialization of pharmaceuticals, vaccines, and biosimilars. Its primary market is India, with operations segmented into Vaccines and Formulations. The company's pharmaceutical offerings comprise proprietary medicines targeting diverse medical fields such as pain management, diabetes, cardiovascular health, oncology, renal disease, osteoporosis, anti-tubercular therapy, and gastro-intestinal care. In addition to these, Panacea Biotec develops and distributes vaccines for conditions like anthrax, dengue, and Japanese encephalitis, among others. The firm maintains a robust global presence, exporting its goods to over 30 countries, including key markets such as the United States, Germany, the Russian Federation, Sri Lanka, and the Philippines. Notably, Panacea Biotec has established significant strategic alliances, including a partnership with the Russian Direct Investment Fund for the manufacture of the Sputnik-V COVID-19 vaccine. It also collaborates with the Coalition for Epidemic Preparedness Innovations (CEPI) and the Translational Health Science and Technology Institute (THSTI) to pioneer vaccine candidates designed to combat SARS-CoV-2 variants and other beta coronaviruses.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Piramal Pharma Limited
―
Supriya Lifescience Limited
―
Syngene International Ltd.
―